We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

UPLL:LSINUPL Limited Sponsored GDR RegS Analysis

Data as of 2026-03-12 - not real-time

$13.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

UPL Limited GDR is trading at $13, well below its 20‑day SMA of 16.80 and 50‑day SMA of 16.50, indicating a technical discount. The RSI 14 sits at 18.99, signaling oversold conditions, while the MACD line is negative and the signal line is positive, giving a bearish MACD indication. The price is perched on a key support level of 13 with resistance around 18.10, suggesting a potential bounce if buying pressure returns. Volatility is extremely high at over 101% for the past 30 days, and beta is low (0.14), meaning price swings are large but not strongly tied to market moves. The Fear‑Greed Index reads 78.16 (Extreme Greed), implying market optimism despite the stock’s weak fundamentals. Fundamentally, revenue has contracted by 17.2% year‑over‑year, margins are thin (gross margin ~48%, operating margin ~15%), and the debt‑to‑equity ratio is a staggering 67.6, dwarfing the modest cash reserves. The dividend yield of 1.39% appears attractive, but a payout ratio of 27% may be hard to sustain given the cash‑flow strain. Overall, the stock presents a classic oversold technical picture against a backdrop of deteriorating earnings, high leverage, and elevated price volatility. Investors should weigh the short‑term upside potential against the long‑term structural challenges before deciding on exposure.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • RSI indicating oversold conditions
  • Price resting on strong support at $13
  • High short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 4/10

Key Factors

  • Negative revenue growth and thin margins
  • Elevated debt‑to‑equity ratio
  • Unclear path to earnings recovery

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Sustained high leverage
  • Persistently weak profitability
  • Questionable dividend sustainability

Key Metrics & Analysis

Financial Health

Revenue Growth-17.20%
Profit Margin5.53%
Debt/Equity67.57

Technical Analysis

TrendBullish
RSI19.0
Support$13.00
Resistance$18.10
MA 20$16.80
MA 50$16.50
MA 200$15.43
MACDBearish
VolumeDecreasing
Fear & Greed Index78.16

Valuation

GradeUndervalued
TypeValue
Dividend Yield1.39%

Risk Assessment

Beta0.14
Volatility101.21%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.